Component Analysis and Determination of Bioactivity of Oriental Therapeutic Drug for Hepatitis B

간염 치료제인 민간제제의 성분 분석 및 생리 활성 검색

  • 김승호 (한국과학기술연구원 유전공학연구소 단백질화학연구실) ;
  • 이종우 (한국과학기술연구원 유전공학연구소 단백질화학연구실) ;
  • 이현선 (미생물공학연구실) ;
  • 함경수 (한국과학기술연구원 유전공학연구소 단백질화학연구실)
  • Published : 1992.12.01

Abstract

An oriental drug, named NP-S, traditionally used as a therapeutic agent for hepatitis B was characterized by separating into volatile and non-volatile fractions. The volatile fraction contained ammonia as determined by ammonia kit and eight peaks when it was analyzed by gas chromatography that are not identified yet. The elemental analysis showed that the non-volatile fraction contained 15.5% carbon, 4.8% hydrogen, 11% nitrogen, and 10% sulfur along with a few trace elements such as Cl, Si, Mg and Zn. NP-S contained 6.7% peptide, 0.3% free amino acids such as Lys, Pro, Arg, lie, Tyr, Phe, His, Thr and Ser and 0.1% inorganic phosphate. The drug showed antimicrobial activity against Salmonella typhimurium, StaPhylococcus aureus and Candida albieans and also had antioxidant activity when thiobarbituric acid reacting substances(TBARS) method was applied.

본 연구에서는 간염치료제로 효과가 있는 민간제제(NS-P)의 성분 분석 및 항균 활성과 항산화 활성을 연구하였다. 이 NP-S는 그람 양성균인 Staphylococcus aureus와 그람 음성균인 Salmonella typhimurium 그리고 진균인 Candida albcans에 항균 활성을 보여 주었을 뿐만 아니라, 지질의 과산화를 억제하는 항산화 활성을 나타냈다. 이러한 NP-S는 C/H/N/S의 원소비가 15.5/4.8/11/10으로 황(S)이 상당히 많이 존재하고 있으며, 휘발성 물질인 암모니아를 2.11M 함유하고 있었다. 이 외에도 6.7의 펩타이드, 0.3의 유리 아미노산, 0.1의 무기 인산염을 함유하고 있으며, 미량 원소로서 Cl, Si, Mg, Zn도 함유하고 있다.

Keywords

References

  1. Proc. Natl. Acad. Sci. USA v.82 Expression in E. coli of a cloned DNA sequence encoding the pre-S2 region of hepatitis B virus Offensperger,W.;S.Wahl;A.R.Neurath;P.Price;N.Strick;S.B.H.Kent;J.K.Christman;G.Acs
  2. J. Immunol. v.145 Hepatitis B virus nucleocapsid/pre-S2 fusion proteins expressed in attenuated Salmonella for oral vaccination Schodel,F.;D.R.Milich;H.Will
  3. Sci. Am. v.248 Synthetic vaccines Lerner,R.A.
  4. Proc. Natl. Acad. Sci. USA v.86 Vaccine engineering: enhancement of immunogenicity of synthetic peptide vaccines related to hepatitis in chemically defined models consisting of T- and B-cell epitopes Tam,J.P.;Y.A.Lu
  5. JAMA v.239 Effect of vidarabine on chronic hepatitis B virus infection Pollard,R.P.;E.A.Smith;E.A.Neal;P.B.Gregory;T.C.Merigan;W.S.Robinson
  6. Gastroenterology v.80 Adenine arabinoside therapy in HBsAg-positive chronic liver disease: A controlled study Bassendine,M.F.;R.G.Chadwick;J.Salmerson;U.Shipton;H.C.Thomas;S.Sherlock
  7. Gastroenterology v.88 Comparative efficacy of adenine arabinoside 5'-monophosphate and prednisone withdrawal followed by adenine arabinoside 5'-monophosphate in the treatment of chronic active hepatitis type B Perrillo,R.P.;F.G.Regenstein;C.J.Bodicky;C.R.Campbell;G.E.Sanders;Y.C.Sunwoo
  8. N. Engl. J. Med. v.293 Effects of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis Greenberg,H.B.;R.B.Pollard;L.I.Butwick;P.B.Gregory;W.S.Bobinson;T.R.C.Merigan
  9. Lancet v.1 Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection Alexander,G.J.M.;J.Braha;E.A.Fagan;H.M.Smith;H.M.Daniels;A.L.W.F.Eddleston;R.Willams
  10. Liver v.7 Prolonged (6 months) treatment of chronic hepatitis B virus infection with recombinant leukocyte interferon Carreno,V.;J.C.Porres;I.Mora;J.Bartolome;C.Bas;J.Gutiez;J.Cortes;C.H.Guio
  11. Kor. J. Biochem. Isolation of antioxidant compound from therapeutic agent for hepatitis B viral infection Kim,S.H.;H.J.Yeom;H.M.Kim;H.S.Lee;K.S.Hahm
  12. Arch. Biochem. Biophys. v.283 An in vitro model to test relative antioxidant potential: ultraviolet-induced lipid peroxidation in liposomes Pelle,E.;D.Maes;G.A.Padulo;E.K.Kim;W.P.Smith
  13. 肝藤 v.22 各種肝疾患における過酸化脂質および superoxide dismutase 活性の動態 山中恒夫;井戶健一;木村 健;樓林郁之介;河合 忠
  14. 醫學のおゆみ v.122 種種の肝疾患における血淸 superoxide dismutaseの生物物學的活性値と免疫學的活性値 택목준이;稻垣孝雄;加藤勝久;伊藤良一;小池正人;瀧谷 敏;松浦 衛;伊藤吉將;平野和行